We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.06% | 33.31 | 32.87 | 34.09 | 33.64 | 33.29 | 33.4927 | 19,012 | 21:28:42 |
From Jun 2021 to Jun 2024
By Pierre Bertrand
Merck KGaA said Friday that it has discontinued a Phase 2 trial for berzosertib in combination with topotecan in patients with relapsed, platinum-resistant small-cell lung cancer.
The German pharmaceuticals and chemicals company said that, following an interim analysis, the study was discontinued due to low probability of meeting the pre-defined objective of the trial.
"SCLC remains a difficult-to-treat disease, with minimal advances in the past 20 years," Merck said, adding that it will continue external studies exploring berzosertib in additional combinations and clinical settings.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
June 03, 2022 10:06 ET (14:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
